Alignment Healthcare (ALHC) Q4 2022: ACO REACH Grows 52% as Margin Leverage Extends Beyond California

February 28, 2023 | By EarningsIQ Research

Alignment Healthcare’s disciplined execution in California is now translating to new markets, with ACO REACH membership up 52% and operating leverage emerging across the business. The company’s Care Anywhere model and AVA Insights platform are driving measurable reductions in utilization and costs, supporting both Medicare Advantage and ACO REACH growth. 2023 guidance signals confidence in core margin trends, even as the company absorbs new member headwinds and prepares for a more competitive bid cycle.

Summary

• Clinical Model Replication: Alignment’s AVA-powered Care Anywhere model is producing measurable cost and utilization improvements in new states.
• Margin Leverage Materializing: Operating efficiency and cohort MBR improvements are extending beyond California, supporting the path to break-even.
• Strategic Expansion: ACO REACH and new market entries are positioned as incremental growth drivers without compromising core MA focus.

Business Overview

Alignment Healthcare operates as a tech-enabled Medicare Advantage (MA) and ACO REACH plan, generating revenue primarily through capitated payments from CMS for managing senior healthcare. Its business is built around two principal segments: Medicare Advantage, the core insurance plan for seniors, and ACO REACH, a value-based care program that aligns with provider partners to manage traditional Medicare beneficiaries. The company’s AVA Insights analytics platform and Care Anywhere clinical teams underpin its care delivery and cost management strategy across markets.

Performance Analysis

Alignment delivered double-digit revenue and membership growth in 2022, with total revenue up 23% and MA membership increasing 14% year-over-year. The company’s medical benefit ratio (MBR) improved to 86.5% for the year, reflecting strong cost management and clinical outcomes, particularly in its California market, which turned adjusted EBITDA positive. Adjusted EBITDA loss narrowed as operating leverage began to emerge, with SG&A ratio improving by 140 basis points year-over-year, even as the company invested in new market expansion and public company infrastructure.

Outside California, new market performance outpaced expectations, with inpatient admissions per thousand running at or below established benchmarks. The ACO REACH segment, which grew 52% in aligned beneficiaries, contributed over $130 million in revenue—more than 150% growth year-over-year—and is expected to generate incremental margin as cohorts mature. Membership retention improved, especially in California, while new member acquisition in states outside California accelerated, up more than 60% year-over-year.

• Cost Discipline Evident: SG&A efficiency and cohort MBR improvements are driving operating leverage as the business scales.
• Clinical Outcomes Translate to Margin: Care Anywhere members show 32% lower institutional claims expense and 47% fewer ER visits than traditional Medicare, fueling lower MBRs and richer benefits.
• New Market Traction: Early success in Fresno, North Carolina, and other new markets validates the replicability of Alignment’s clinical model.

While ACO REACH currently runs at a higher MBR, management expects embedded earnings power to increase as the population matures and clinical programs take effect. The company’s guidance for 2023 reflects continued growth and incremental margin improvement, with a clear path to break-even targeted for 2024.

Executive Commentary

Strategic Positioning

1. Core Clinical Model Scalability

Alignment’s ability to replicate its Care Anywhere and AVA Insights model in new markets is a central strategic lever. New states are already achieving inpatient admission rates near or better than California benchmarks, supporting the case for national expansion and margin improvement over time.

2. Dual Engine Growth: MA and ACO REACH

The company is maintaining its 20% MA revenue growth target while treating ACO REACH as a complementary, capital-efficient growth vector. ACO REACH leverages existing provider relationships and requires minimal incremental SG&A, supporting incremental revenue without diluting focus on the core MA franchise.

3. Margin Expansion Through Cohort Management

MBR improvement among returning members is a persistent theme, with year-one to year-six cohorts showing a 10% MBR improvement. This margin expansion funds richer product benefits and supports Alignment’s competitive positioning in a tightening reimbursement environment.

4. Distribution and Product Optimization

Leadership is doubling down on enterprise-wide STARS performance, optimizing rebate allocation, and retooling distribution strategy—especially in new markets—to ensure not just entry, but market leadership. Internal sales and digital channels are being added to complement broker-driven growth.

5. Capital Efficiency and Break-Even Pathway

Management’s guidance and commentary reinforce a disciplined approach to capital allocation, with no need for additional financing to fund organic growth. SG&A leverage and clinical cost containment are expected to drive the company to adjusted EBITDA break-even in 2024.

Key Considerations

This quarter underscores Alignment’s transition from a California-centric operator to a scalable national platform, with a proven clinical model and a disciplined approach to margin management and growth.

Key Considerations:

• Clinical Model Validation: Replication of Care Anywhere outcomes in new markets is critical for sustained national growth and future margin improvement.
• ACO REACH as Incremental Growth: The capital-light expansion of ACO REACH leverages existing provider networks and diversifies revenue without significant new SG&A burden.
• Margin Leverage from Cohort Maturity: Continued improvement in returning member MBRs is a key funding source for product competitiveness and profitability.
• Distribution Strategy Adjustment: Success in new markets will depend on refining sales channels and deepening provider partnerships beyond California.

Risks

Alignment faces reimbursement and regulatory headwinds, including higher STARS cut points, rate pressure, and risk adjustment changes that could disproportionately affect vulnerable populations. Competitive intensity is rising in both established and new markets, and aggressive benefit design by rivals could pressure both growth and margin. Execution risk remains in scaling operational excellence outside California and maturing ACO REACH cohorts to target profitability.

Forward Outlook

For Q1 2023, Alignment guided to:

• Health plan membership between 109,300 and 109,500
• Revenue of $429 million to $434 million
• Adjusted gross profit of $38 million to $41 million
• Adjusted EBITDA loss of $17 million to $14 million

For full-year 2023, management maintained guidance:

• Revenue of $1.705 billion to $1.730 billion
• Adjusted gross profit of $205 million to $217 million
• Adjusted EBITDA loss of $34 million to $20 million
• Health plan membership of 113,000 to 115,000

Management highlighted:

• Continued focus on cohort MBR improvement, especially among returning members
• Operating leverage through SG&A efficiency and disciplined cost management

Takeaways

Alignment’s Q4 results mark a strategic inflection point, as the Care Anywhere model’s cost and utilization benefits are now visible in new markets and ACO REACH. The company’s disciplined capital and operating approach positions it for break-even in 2024, even as it absorbs new member and regulatory headwinds.

• Margin Expansion is Cohort-Driven: Improvement in returning member MBRs is the engine for funding richer benefits and future profitability.
• Strategic Expansion is Capital-Efficient: ACO REACH leverages existing provider relationships and drives incremental revenue with minimal new SG&A.
• 2023 Will Test Replicability and Distribution: Success in new markets hinges on clinical model scalability and a retooled distribution strategy.

Conclusion

Alignment Healthcare’s disciplined execution and scalable clinical model are enabling it to extend margin leverage and growth beyond California. With ACO REACH and new market traction, the company is positioned to weather industry headwinds and deliver on its break-even trajectory in 2024.

Industry Read-Through

Alignment’s results reinforce that scalable, analytics-driven care management models are increasingly critical to margin and growth in Medicare Advantage and value-based care. Operators with proven ability to replicate clinical and cost outcomes across geographies will be better positioned as CMS tightens reimbursement and competitive intensity rises. Capital-efficient expansion, disciplined rebate allocation, and STARS performance are emerging as key differentiators. For the broader industry, the shift from volume to value and the need for SG&A leverage will separate sustainable operators from those reliant on aggressive benefit design or short-term subsidies.

ALHC Healthcare Managed Care Medicare Advantage ACO REACH Value-Based Care Clinical Model Margin Expansion